Results: Compared with subjects with AGR ≥ 1.5, subjects with 1.1 > AGR ≥ 1.0 and 1.0 > AGR showed adjusted hazard ratio (aHR) 2.69 (95% confidence interval, CI, 1.54-4.72) and aHR 6.71 (95% CI 3.56-12.66) for all-cause mortality, aHR 2.95 (95% CI 1.42-6.11) and aHR 4.38 (95% CI 1.57-12.25) for cancer mortality, and aHR 2.07 (95% CI 1.28-3.36) and aHR 3.99 (95% CI 2.10-7.58) for cancer incidence, respectively. When cancer incidence events after 2 years from baseline were separately analyzed, subjects with 1.1 > AGR ≥ 1.0 and 1.0 > AGR were associated with aHR 1.88 (95% CI 1.01-3.48) and aHR 2.55 (95% CI 1.03-7.11) for cancer incidence, respectively. Cancer events were increased in all types of cancer, but especially in liver and hematologic malignancies.
Conclusions: Low AGR is a risk factor for cancer incidence and mortality, both short-and long terms, in a generally healthy screened population. The results of this study need to be replicated in larger studies, along with the determination of the sensitivity and other diagnostic values of low AGR. Key words: albumin, total protein, albumin-to-globulin ratio, chronic inflammation, cancer introduction Although low albumin-to-globulin ratio (AGR), calculated as serum albumin/(total protein − albumin), has mainly been used as a clinical indicator for multiple myeloma or other immunoproliferative diseases [1, 2] , its two components have been separately reported to be associated with a wide array of chronic diseases. Increased serum globulins have been associated with cancer, rheumatoid diseases, chronic liver disease, nephrotic syndrome, diabetes mellitus, and more, and decreased albumin has been associated with chronic infections, chronic liver disease, and nephrotic syndrome [3, 4] .
In a recent study, low AGR has been reported to predict longterm mortality in breast cancer patients [5] . The result of this particular study was consistent with previous studies that associated low serum albumin with increased long-term mortality in various malignancies, including breast, lung, gastric, colorectal, and pancreatic cancer [6] [7] [8] [9] .
As such, previous studies have only been based on cancer patients, and there is no study that investigated the association of low AGR with incidence of chronic diseases, including cancer, in healthy populations. We have investigated low AGR as a risk factor for cancer incidence and mortality in a generally healthy population.
methods study population
We retrospectively enrolled 28 292 consecutive Korean adults older than 30 years and younger than 80 years who received general routine health evaluation at Seoul National University Hospital (SNUH) Health Promotion Center (HPC) from 1 January 2003 to 31 December 2010. Subjects with history of major chronic disease were excluded: coronary heart disease (n = 331), stroke (n = 142), cancer (n = 214), liver cirrhosis (n = 94), chronic obstructive lung disease (n = 88), complicated diabetes (with end-organ damage) (n = 128), end-stage renal disease (represented by those with estimated glomerular filtration rate using the MDRD formula <30 ml/min) (n = 17), and those with serum albumin <3.2 g/dl (n = 17). Additionally, subjects with serum white blood cell count greater than 12.0 × 10 9 /l (n = 221) were excluded to exclude subjects with probable acute inflammation at baseline. After further excluding those with missing laboratory results or insufficient medical records (n = 66), a total of 26 974 Korean adults older than 30 years and younger than 80 years were selected. This retrospective study was approved by the SNUH Institutional Review Board and the requirement for informed consent was waived.
data collection
Medical history of hypertension, diabetes mellitus, hyperlipidemia, current medication profile, and current smoking status were inquired by selfreported questionnaire. Serum albumin, total protein, white blood cell count, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), hemoglobin A1c (HbA1c), and creatinine were measured after at least 12-h fasting period on the same day of the study. Hypertension was defined as self-reported history of hypertension and/or use of antihypertensive medication or a blood pressure ≥140/90 mmHg. Diabetes was defined as selfreported history of diabetes and/or use of oral hypoglycemic medication or subcutaneous insulin or HbA1c ≥6.5%. Hyperlipidemia was defined as selfreported history of hyperlipidemia and/or use of lipid-lowering agents or LDL-c ≥160 mg/dl or TC ≥240 mg/dl. We used Korean National Health Insurance (KNHI) medical service claims data that cover virtually all Koreans except for Medicaid beneficiaries (∼3% of the population), including registered diagnosis data coded using the International Classification of Diseases, 10th revision (ICD-10), as well as KNHI claims data on radiation therapy, surgical operations for cancer, and prescription claims for chemotherapeutic agents within 1 year since the first diagnosed date (as cancer i.e. ICD-10 C00-C97) to determine previous history of cancer, if the claims data were registered before the date of visitation, and also to determine cancer incidence, if the claims data were registered after the date of visitation. KNHI medical service claims data were also used to determine previous history of coronary heart disease (I20-I25), stroke (I60-I64), liver cirrhosis (K70.3, K74), chronic obstructive lung disease (J42-J44), complicated diabetes mellitus (G59.0, G63.2, H28.0, M14.2, N08.3), and chronic liver disease (B18, E03, E27, K73) if the diagnosis registered was before the date of visitation.
Korean death registry from the Korean National Statistical Office was used to retrieve mortality data, including data on cause of death, from 1 January 2002 until 31 December 2011. Cause of death registered as ICD-10 codes C00-C97 was determined to represent cancer mortality.
statistical analysis
AGR was defined as serum albumin/(total protein − albumin), as previously described [5] . Subjects were categorized into five groups according to their AGR levels: AGR ≥ 1.5, 1.5 > AGR ≥ 1.2, 1.2 > AGR ≥ 1.1, 1.1 > AGR ≥ 1.0, and 1.0 > AGR.
Cox proportional hazards regression models were used to determine the association between low AGR and all-cause and cancer mortality, as well as cancer incidence and non-liver cancer incidence, for both all events and for events 2 years after baseline (i.e. first visitation date), in order to differentially investigate short-and long-term events, as previously implemented [10] . Adjusted covariates were age, sex, current smoking, BMI, and history of chronic liver disease. Kaplan-Meier survival analysis was used to describe the relationship between AGR levels and all-cause mortality, cancer mortality, cancer incidence, and non-liver cancer incidence. Fisher's exact test was employed to determine the association between low AGR (classified in binary as AGR < 1.1 versus AGR ≥ 1.1 due to a limited number of subjects with each cancer types) and different cancer types, as well as different cancer classifications by biology as smoking-related, alcohol-related, hormonerelated, and others, similar to how it was previously described [11] . Subjects with low AGR (<1.1) upon first visitation for health checkup at SNUH HPC were subsequently investigated for specific clinical information via SNUH chart review (n = 500). However, follow-up clinical information was not available for all subjects, for only a proportion of subjects (n = 126) continued to visit SNUH. The clinical characteristics of these patients were reviewed, and those diagnosed with cancer were reviewed in detail, including information on staging (n = 18). All statistical analysis was carried out under STATA version 12.1 (StataCorp, College Station, TX, USA). All results were considered significant for P-values <0.05.
results characteristics of the study population
The clinical characteristics of the study population at baseline are summarized in Table 1 . The mean age was 52.0 ± 10.3 years, 50.5% were male, 19.1% were current smokers, 8.8% were underweight, whereas 34.0% were obese. Chronic liver disease before visitation was observed in 11.2% of subjects. There were 105 subjects with AGR < 1.0 (0.4%), and 395 subjects with 1.0 ≤ AGR < 1.1 (1.5%).
Median follow-up time for survival was 5.9 years (interquartile range 4.1 years) for all mortality events, and 6.4 years (interquartile range 3.4 years) for all mortality events after 2 years since baseline.
AGR levels and mortality
Relationships between AGR levels and all-cause mortality, and cancer mortality, for all events since baseline are demonstrated in Kaplan-Meier curves in Figure 1A and B. Compared with subjects with AGR ≥ 1.5, subjects with 1.1 > AGR ≥ 1.0 showed adjusted hazard ratio (aHR) 2.69 with 95% confidence interval (95% CI) 1.54-4.72 for all-cause mortality and aHR 2.95 (95% CI 1.42-6.11) for cancer mortality, and those with 1.0 > AGR showed aHR 6.71 (95% CI 3.56-12.66) for all-cause mortality and aHR 4.38 (95% CI 1.57-12.25) for cancer mortality (Table 2) . Hazards ratios remained similar (slightly attenuated in degree) even when mortality events after 2 years from baseline were separately analyzed.
AGR levels and cancer incidence
Relationships between AGR levels and cancer incidence, and non-liver cancer incidence, for all events since baseline are demonstrated in Kaplan-Meier curves in Figure 1C and D. Compared with subjects with AGR ≥ 1.5, subjects with 1.1 > AGR ≥ 1.0 showed aHR 2.07 (95% CI 1.28-3.36) for all cancer incidence and aHR 1.47 (95% CI 0.85-2.56) for non-liver cancer incidence, and those with 1.0 > AGR showed aHR 3.99 (95% CI 2.10-7.58) for all cancer incidence, and aHR 3.12 (95% CI 1.53-6.38) for non-liver cancer incidence (Table 2) . Hazards ratios remained similar (slightly attenuated in degree) when events after 2 years from baseline were separately analyzed. Compared with subjects with high AGR (≥1.1), subjects with low AGR (<1.1) were associated with an increased cancer risk for all major cancer types in general (although some associations were insufficient in statistical power), but especially high risk was observed for liver and hematologic malignancies, although hematologic malignancies (which includes multiple myeloma) were remarkably low in incidence, as presented in Table 3 .
clinical characteristics of low AGR subjects
Among the 126 subjects with low AGR who were followed up at SNUH after their visitation to SNUH HPC for health checkup, 18 (14.3%) were eventually diagnosed with cancer (for shortand long-term follow-up), 20 (15.9%) had chronic liver disease (including chronic hepatitis B, chronic hepatitis C, and alcoholic hepatitis), and 26 (20.6%) had conditions reflecting chronic inflammation, including autoimmune diseases, and bronchiectasis. Remarkably, there were 8 (6.3%) subjects with bronchiectasis. For the 18 subjects diagnosed with cancer, we showed their detailed clinical characteristics in Supplementary Table S1 , available at Annals of Oncology online. Among those subjects, 1 (5.6%) had metastatic disease.
discussion
In our relatively large retrospective cohort study, we have identified subjects with low AGR, incidentally found in a general healthy screened population, at risk for increased all-cause mortality, cancer mortality, and cancer incidence. This is rather remarkable as low AGR is determined by serum albumin and total protein levels which are blood tests included in commonly administered routine laboratory tests, and because apparently a relatively common subpopulation with ∼2% prevalence in our study was observed to have low AGR values. Subjects with low Multivariable Cox proportional hazards models adjusted for age, sex, current smoking, body mass index, and previous history of chronic liver disease. aHR, adjusted hazard ratio; CI, confidence interval; AGR, albumin-to-globulin ratio. AGR were found to be at risk for not only liver cancer or hematologic malignancies, but all the other common cancers as well (Table 3) . Moreover, this increased risk was not only limited to short-term follow-up of within 2 years, but also to long-term follow-up of beyond 2 years. Our results are remarkably plausible as they consistently show clear dose-response relationship in terms of AGR levels. Furthermore, pre-existing conditions have been extensively excluded and our analysis adjusted for baseline characteristics including specific laboratory values, with near complete follow-up for mortality and incidence. Subjects with low AGR (<1.1) were apparently healthy in general without an overwhelmingly high prevalence of chronic liver disease, especially since we initially excluded those with hypoalbuminemia (<3.2 g/dl) (n = 17), those with major chronic disease, including liver cirrhosis (n = 94), as well as those with probable acute inflammation. Our results remained significant, refuting the possibility that the association between the outcomes and low AGR was caused by the aforementioned conditions.
Considering the fact that low AGR was associated with an increased risk for cancer incidence and mortality for both short-and long-term follow-up, in addition to the fact that a wide spectrum of cancer types was implicated, low AGR may reflect a general common pathway to carcinogenesis. Chronic inflammation may be a good explanation, as it has been widely accepted to be linked to carcinogenesis [12, 13] , based on observations of cancer rising at sites of chronic inflammation and inflammatory cells being present in tumor sites [13, 14] . The association of low AGR to cancer is synonymous to previous studies linking elevated markers of chronic inflammation, e.g. C-reactive protein, with cancer incidence and mortality in generally healthy populations [15, 16] . In fact, many subjects with low AGR were shown to have conditions reflecting chronic inflammation, such as rheumatoid arthritis or bronchiectasis. There is sufficient biological plausibility in attributing chronic inflammation as the link between low AGR and increased cancer incidence and mortality, as increased expression of inflammatory cytokines may elevate total protein levels [17, 18] , and this may also cause hypoalbuminemia by suppressing albumin synthesis in the liver [19, 20] .
The association between low AGR and increased total mortality is also a noteworthy observation of our study, and just like carcinogenesis, chronic inflammation is a very plausible explanation for this as well. Not only has chronic inflammation been association with carcinogenesis as aforementioned, but it has also been associated with various other conditions such as atherosclerotic diseases [21] , insulin resistance [22] , autoimmune diseases [23] , and so on, that are associated with mortality risk in general. Although our study focused on the association of low AGR with cancer, larger studies, or case-control studies focused on cardiovascular disease, autoimmune diseases, etc., would most likely reveal the association of low AGR with other conditions related to chronic inflammation.
It is interesting to note that 250 of 500 subjects with low AGR (<1.1), half the subjects, had normal range for both serum albumin (3.2-5.2 g/dl) and total protein (6.0-8.0 g/dl), likely to go unnoted in the clinic. We tentatively suggest that AGR should be calculated more often in the clinic, if not routinely, to screen for low AGR, which our study suggests to be a useful clinical indicator for cancer incidence and mortality.
There are several limitations to our study. First, many of the clinical factors, including cancer diagnosis, used in our study were based on national medical service claims data that may not be completely accurate. Nonetheless, in order to overcome such limitation, we have specified our criterion for cancer diagnosis with comprehensive medical service claims data on specific surgical operations for cancer, radiation therapy, and/or chemotherapy, which are accurate claims data since they involve actual transaction in payment, in contrast to diagnosis registration being sometimes overcoded by physicians. Secondly, although our study population was based on a generally healthy population it was not a population-based study, so our results cannot be generalized. Future large-scale population-based prospective cohort studies are needed to fully consolidate the results of our study, especially in terms of the benefit of screening for low AGR at a population level.
Despite the aforementioned limitations, our study has important clinical implications. To our knowledge, we are the first to show that low AGR, determined from serum albumin and total protein which are part of routinely administered laboratory tests, may be a clinical indicator associated with both short-and long-term risk for cancer incidence and mortality. Future population-based large prospective studies, as well as studies to determine diagnostic values of AGR, are needed to consolidate our findings and to develop specific guidelines on how to manage subjects screened with low AGR. 
